New Test for Diagnosing Neuroendocrine Tumours
Author Information
Author(s): Bernini G P, Moretti A, Ferdeghini M, Ricci S, Letizia C, D'Erasmo E, Argenio G F, Salvetti A
Primary Institution: Department of Internal Medicine and of Oncology, University of Pisa, Pisa
Hypothesis
Can plasma chromogranin A (CgA) be a sensitive and specific marker for phaeochromocytoma and other neuroendocrine tumours?
Conclusion
The study found that CgA is a highly sensitive marker for gastroenteropancreatic tumours and, when combined with catecholamines, can accurately detect phaeochromocytoma.
Supporting Evidence
- Plasma CgA levels were significantly higher in patients with phaeochromocytoma and neuroendocrine tumours compared to controls.
- Combined measurement of CgA and catecholamines improved sensitivity for detecting phaeochromocytoma to 100%.
- CgA was the only circulating marker of disease in some cases of neuroendocrine tumours.
Takeaway
This study shows that a new blood test can help doctors find certain types of tumors in the body, making it easier to diagnose them.
Methodology
The study measured plasma catecholamines and CgA using high-performance liquid chromatography and a two-site sandwich immunoradiometric assay.
Participant Demographics
121 patients with various conditions including phaeochromocytoma, other neuroendocrine tumours, solid nonfunctioning adrenocortical tumours, and essential hypertension, plus 130 normal controls.
Statistical Information
P-Value
P<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website